Nuha Zackariya

Nuha Zackariya

Auto-generated profile, based on publicly available information

Nuha Zackariya

Department of Internal Medicine, Indiana University School of Medicine South Bend Campus, Notre Dame, IN 46617, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OVOksana Volod
Oksana Volod
Connor BunchConnor Bunch
Connor Bunch
NZNuha Zackariya
Nuha Zackariya
EMErnest Moore
Ernest Moore
HMHunter B. Moore
Hunter B. Moore
MWMark M. Walsh
Mark M. Walsh
Viscoelastic hemostatic assay (VHAs) are whole blood point-of-care tests that have become an essential method for assaying hemostatic competence in liver transplantation, cardiac surgery, and most recently, trauma surgery involving hemorrhagic shock. It has taken more than three-quarters of a century of research and clinical application for this technology to become mainstream in these three clinical areas. Within the last decade, the cup and pin legacy devices, such as thromboelastography (TEG® 5000) and rotational thromboelastometry (ROTEM® delta), have been supplanted not only by cartridge systems (TEG® 6S and ROTEM® sigma), but also by more portable point-of-care bedside testing iterations of these legacy devices (e.g., Sonoclot®, Quantra®, and ClotPro®). Here, the legacy and new generation VHAs are compared on the basis of their unique hemostatic parameters that define contributions of coagulation factors, fibrinogen/fibrin, platelets, and clot lysis as related to the lifespan of a clot. In conclusion, we offer a brief discussion on the meteoric adoption of VHAs across the medical and surgical specialties to address COVID-19-associated coagulopathy.

1 January 2019 in Journal of Addiction
Verified
Journal Article
Open access
PDF file
DZDavid I. Zimmer
David I. Zimmer
RMRoss McCauley
Ross McCauley
VKVarun Konanki
Varun Konanki
JDJoseph Dynako
Joseph Dynako
NZNuha Zackariya
Nuha Zackariya
MWMark M. Walsh
Mark M. Walsh
Background. Chronic cannabis use has become prevalent with decriminalization, medical prescription, and recreational legalization in numerous US states. With this increasing incidence of chronic cannabis use a new clinical syndrome has become apparent in emergency departments and hospitals across the country, termed Cannabinoid Hyperemesis (CH). CH has been described as cyclical vomiting and abdominal pain in the setting of chronic cannabis use, which is often temporarily relieved by hot showers. CH presents a diagnostic challenge to clinicians who do not have a high clinical suspicion for the syndrome and can result in high costs and resource utilization for hospitals and patients. This study investigates the expenditures associated with delayed CH evaluation and delayed diagnosis. Methods. This is a retrospective observational study of 17 patients diagnosed with CH at three medical centers in the United States from 2010 to 2015, consisting of two academic centers and a community hospital. Emergency department (ED) costs were calculated and analyzed for patients eventually diagnosed with CH. Results. For the 17 patients treated, the total cost for combined ED visits and radiologic evaluations was an average of $76,920.92 per patient. On average these patients had 17.9 ED visits before the diagnosis of CH was made. Conclusion. CH provides a diagnostic challenge to clinicians without a high suspicion of the syndrome and may become increasingly prevalent with current trends toward cannabis legalization. The diagnosis of CH can be made primarily through a thorough history and physical examination. Awareness of this syndrome can save institutions money, prevent inappropriate utilization of healthcare resources, and save patients from unnecessary diagnostic tests.

Verified
Journal Article
Open access
PDF file
Connor BunchConnor Bunch
Connor Bunch
Anthony ThomasAnthony Thomas
Anthony Thomas
John StillsonJohn Stillson
John Stillson
LGLaura Gillespie
Laura Gillespie
RKRashid Z. Khan
Rashid Z. Khan
MWMark M. Walsh
Mark M. Walsh
Background: The treatment of COVID-19 patients with heparin is not always effective in preventing thrombotic complications, but can also be associated with bleeding complications, suggesting a balanced approach to anticoagulation is needed. A prior pilot study supported that thromboelastography and conventional coagulation tests could predict hemorrhage in COVID-19 in patients treated with unfractionated heparin or enoxaparin, but did not evaluate the risk of thrombosis. Methods: This single-center, retrospective study included 79 severely ill COVID-19 patients anticoagulated with intermediate or therapeutic dose unfractionated heparin. Two stepwise logistic regression models were performed with bleeding or thrombosis as the dependent variable, and thromboelastography parameters and conventional coagulation tests as the independent variables. Results: Among all 79 patients, 12 (15.2%) had bleeding events, and 20 (25.3%) had thrombosis. Multivariate logistic regression analysis identified a prediction model for bleeding (adjusted R2 = 0.787, p < 0.001) comprised of increased reaction time (p = 0.016), decreased fibrinogen (p = 0.006), decreased D-dimer (p = 0.063), and increased activated partial thromboplastin time (p = 0.084). Multivariate analysis of thrombosis identified a weak prediction model (adjusted R2 = 0.348, p < 0.001) comprised of increased D-dimer (p < 0.001), decreased reaction time (p = 0.002), increased maximum amplitude (p < 0.001), and decreased alpha angle (p = 0.014). Adjunctive thromboelastography decreased the use of packed red cells (p = 0.031) and fresh frozen plasma (p < 0.001). Conclusions: Significantly, this study demonstrates the need for a precision-based titration strategy of anticoagulation for hospitalized COVID-19 patients. Since severely ill COVID-19 patients may switch between thrombotic or hemorrhagic phenotypes or express both simultaneously, institutions may reduce these complications by developing their own titration strategy using daily conventional coagulation tests with adjunctive thromboelastography.

9 October 2018 in Clinical Practice and Cases in Emergency Medicine
Verified
Journal Article
Open access
PDF file
JMJoseph B Miller
Joseph B Miller
MWMark Walsh
Mark Walsh
JMJessica Magyar
Jessica Magyar
NZNuha Zackariya
Nuha Zackariya
JRJohn Rice
John Rice
PGPaul Guentert
Paul Guentert
Author(s): Miller, Joseph; Walsh, Mark; Magyar, Jessica; Zackariya, Nuha; Rice, John; Rice, Katherine; Ziegelmaier, Dawn; Hanlon, Patrick; Dynako, Joseph; Zimmer, David; Shariff, Faadil; McCurdy, Michael T.; Kappler, Shane; Guentert, Paul

31 January 2019 in Pediatric Emergency Care
Verified
Journal Article
Closed access
AGAnne Grisoli
Anne Grisoli
JDJoseph Dynako
Joseph Dynako
DZDavid Zimmer
David Zimmer
NZNuha Zackariya
Nuha Zackariya
FSFaadil Shariff
Faadil Shariff
GDGerard Duprat
Gerard Duprat
We present a case of a 10-year-old girl shot in the thigh by a stray bullet who had a favorable outcome when treated with a multidisciplinary approach at the nearest nonpediatric level II trauma center. Point-of-care thromboelastography facilitated effective resuscitation based on her coagulation profile, minimized blood product use, and allowed for damage-control surgery to stabilize and revascularize her complex femur fracture.

9 August 2019 in Current Opinion in Gynecology and Obstetrics
Verified
Journal Article
Open access
BSBaumgartner S
Baumgartner S
SFShariff F
Shariff F
VSVande Lune Sa
Vande Lune Sa
ZNZackariya N
Zackariya N
GAGrisoli A
Grisoli A
WMWalsh M
Walsh M
This narrative review discusses the history of the pathophysiologic principles and utilization of point-of-care (POC) viscoelastic tests (VETs) in the definition and treatment of postpartum hemorrhage (PPH). This paper addresses the epidemiology of PPH, describes the hemostatic changes that occur in pregnancy and in PPH, and demonstrates the utilization of viscoelastic testing in the identification and treatment of patients with PPH. Additionally, a description of rotational thromboelastometry (ROTEM) and thromboelastography (TEG), the two most commonly used VETs, is detailed in this paper. VETs have only recently been used to guide blood component therapy (BCT) in trauma in the last decade. The recent increased utilization of VETs to guide BCT in PPH is following a similar trend with a delay of ten years. In a similar fashion to the trauma literature, which expanded greatly within this last decade, the literature concerning the use of VETs in PPH has also increased in the last few years. However, because of differing pathophysiologies associated with the coagulopathy of PPH verses traumatic-induced coagulopathy (TIC), utilization of VETs has been more refined and focused on the VETs’ capacity to determine low fibrinogen and to guide the utilization of blood components and prohemostatic agents. The identification and treatment of PPH depends on clinical parameters, conventional coagulation tests (CCTs) including Clauss fibrinogen, and VETs. Successful treatment of PPH will no doubt include utilization of all three strategies with an increasing utilization of VETs in the future.